Ronald Bukowski

1.3k citations
23 papers · 999 · 1 hit paper · h-index 10

Impact in

  • Hematology top 2%
    • Erythropoietin and Anemia Treatment
    • Iron Metabolism and Disorders
  • Biochemistry top 10%
    • Blood transfusion and management

Papers in

    • Cancer Treatment and Pharmacology 3
    • Lung Cancer Research Studies 3
    • Cancer-related Molecular Pathways 2
    • Cancer Immunotherapy and Biomarkers 2
    • Cell death mechanisms and regulation 2

Ronald Bukowski

23 papers receiving 948 citations

Ronald Bukowski's Hit Papers

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. 1997 · 567 citations
5670+9+19Years since publication100200300400500

Peers

Ronald Bukowski
Comparison fields: 5 of 87
  • Hematology 453
  • Biochemistry 72
  • Oncology 287
  • Genetics 98
  • Immunology 148
Replace Jeffrey A. Gilreath with:
Jeffrey A. Gilreath United States
Sven-Åge Killmann Denmark
Charis Matsouka Greece
Andrija Bogdanović Serbia
Michaëla Semeraro France
Evangelos Messaris United States
Thomas A Ratko United States
Benedikt Schaefer Austria
Z Zawadzki United States
Lyonel G. Israels Canada
Ronald Bukowski relative to Jeffrey A. Gilreath United States Jeffrey A. Gilreath's profile →
Citations per field
00.5×2.8×
Jeffrey A. Gilreath · 1×
Citations per year

Countries citing papers authored by Ronald Bukowski

Since Specialization
Citations

This map shows the geographic impact of Ronald Bukowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Bukowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Bukowski more than expected).

Fields of papers citing papers by Ronald Bukowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Bukowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Bukowski. The network helps show where Ronald Bukowski may publish in the future.

Co-authors

The 25 scholars most cited alongside Ronald Bukowski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ronald Bukowski Line = papers co-authored together Ronald Bukowski links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
Hit paper breakdown →
1997567
2 199299
3 200068
4 199766
5 199959
6
The prognostic value of the pT-category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. EORTC-GU group.
199021
7 200420
8 200516
9
The T cell death knell: immune-mediated tumor death in renal cell carcinoma.
200115
10 199912
11
Apoptotic pathways induced by ixabepilone in paclitaxel-refractory ovarian carcinoma cells
20058
12 19988
13 20027
14 19856
15 20036
16 19995
17 20064
18 20014
19 20052
20
HLA-B7 association with low spontaneous cell-mediated cytotoxicity (Sp-CMC) to renal cell carcinoma cell lines.
19772

About Ronald Bukowski

Ronald Bukowski is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Surgery, having authored 23 papers that have together received 999 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (3 papers), Lung Cancer Research Studies (3 papers), Immunotherapy and Immune Responses (3 papers), Lung Cancer Treatments and Mutations (3 papers), Inflammatory mediators and NSAID effects (2 papers), Cell death mechanisms and regulation (2 papers), Cancer-related Molecular Pathways (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Hematology (453 citations), Biochemistry (72 citations), Oncology (287 citations), Genetics (98 citations) and Immunology (148 citations). Ronald Bukowski has collaborated with scholars based in United States, Netherlands and Austria. Frequent co-authors include John A. Glaspy, Simon Tchekmedyian, Saroj Vadhan‐Raj, Carolyn Taylor, Vladimir Kolenko, James H. Finke, Robert G. Uzzo, Patricia Rayman, Martha K. Cathcart and John J. O’Shea. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Blood, The Journal of Urology and Current Pharmaceutical Design.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact